Apathy in Alzheimer’s Disease: Any Effective Treatment?

Table 3

Characteristics and outcome of clinical trials using different classes of compounds on apathy in Alzheimer’s disease.

Study	Study design	Sample size	Intervention	Time	Apathy as a primary or; secondary; objective	Apathy; instrument; assessment	Outcome
Scripnikov et al., 2007 [25]	Randomized, double-blind, placebo-controlled	400	Ginkgo  biloba extract EGb 761; (240 mg/day)	22 weeks	Secondary	Neuropsychiatric Inventory; (NPI)	Significant reduction in NPI apathy scores; with Ginkgo biloba
Siddique et al., 2009 [26]	Retrospective analysis	421	Citalopram; (5–30 mg/day)	12 weeks	Primary	NPI	Use of citalopram was associated with reduced irritability and apathy without sedation